Furthermore, several therapeutic compounds, such as valproic acid, cyclosporine, and cisplatin, are reported to inhibit the function of OCTN2, resulting in secondary carnitine deficiency [75,76,77,78,79]. Here, SLC22A5 is linked to systemic primary carnitine deficiency disease.